Osteoporosis, osteopenia Osteoporosis, osteopenia
Conditions
Interventions
Teriparatide 28.2 microg subcutaneous injection twice a year for two years
Teriparatide
Sponsors
Hamano Takayuki
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with chronic kidney disease stage 4 and 5 and meeting one of the following criteria 1. Meeting criteria for the diagnosis of osteoporosis 2. Trabecular bone score less than -2.0 and T score of bone mineral density more than -2.5 and less than -1.0
Exclusion criteria
Exclusion criteria: 1. Those on maintenance dialysis or expecting the initiation of dialysis within 2 years 2. Those who had kidney transplantation 3. Those on corticosteroid treatment, i.e. prednisolone equivalent dose more than 5mg a day 4. Intact PTH 150 pg/mL and over 5. Bone Paget disease 6. Alkaline phosphatase twice the upper limit of reference range or over 7. Previous radiation therapy to bones 8. Hypercalcemia 9. Primary bone malignancy or metastatic bone malignancy 10. Allergy to teriparatide 11. Pregnant women 12. Previous therapy with teriparatide
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Increase in trabecular bone score in lumbar spine bone mineral density after 2 years | — |
Secondary
| Measure | Time frame |
|---|---|
| Bone mineral densities, trabecular volumetric bone mineral densities and cortical volumetric bone mineral densities measured by 3D SHAPER, trabecular bone score after 1 year, and bone mineral markers such as calcium, phosphate, PTH, bone specific alkaline phosphatase, tartrate-resistant acid phosphatase-5b | — |
Contacts
Public ContactSuzuki Kodai
Nagoya City University Hospital
Outcome results
None listed